Some neurosurgeons advocate for an operation sooner, with the goal of preventing further damage to the trigeminal nerve from unrelieved neurovascular contact. It is unknown whether early versus ...

That’s the brutal reality for sufferers of trigeminal neuralgia, a nerve disorder so painful it’s earned a chilling nickname: the “suicide disease.” Roughly 15,000 Americans are diagnosed ...

Meritus Neurosurgery has introduced a specialized, noninvasive radiosurgery procedure to treat trigeminal neuralgia, a ...

NeuroOne filed its FDA 510(k) for trigeminal nerve ablation months ahead of its revised May 2025 timeline. OneRF system targets trigeminal neuralgia, a condition impacting ~100K in the U.S., using ...

During surgery, veins combined with arachnoid adhesions and arachnoid adhesions alone were observed compressing the trigeminal nerve in seven patients (17.50%) and 33 patients (82.50%), respectively.

The Company had previously projected a submission by the end of June 2025. Trigeminal nerve ablation is a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy ...

Sponsor: Columbus CyberKnifeMost of us associate pain tolerance with temporary experiences—a splitting headache or the ...

NeuroOne Medical Technologies has submitted its 510(k) filing to the FDA for a new treatment option for trigeminal neuralgia earlier than anticipated, indicating efficient progress in product ...

(RTTNews) - NeuroOne Medical Technologies Corp. (NMTC) on Wednesday announced that it has completed its 510(k) submission to the U.S. Food and Drug Administration for its OneRF Trigeminal Nerve ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) filed its 510(k) submission to the FDA for trigeminal nerve ablation on Wednesday, earlier than previously guided. NeuroOne Medical is ...

“If cleared by the FDA, we believe there is a potential to generate revenues from trigeminal nerve ablation in late calendar year 2025.” NeuroOne Medical Technologies Corporation is developing ...

has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.